# Gore Range Capital

> Gore Range Capital is a VC fund backing Health Care and Biotechnology. See 11 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 11
- Last investment: Dec 2024
- Lead investor: 9%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/gore-range-capital/
- Website: https://www.gorerangecapital.com/

Gore Range Capital is a venture capital firm focused on hands-on investing in early-stage healthcare businesses. We invest in companies that have strong potential for growth, high barriers to entry, and exceptional management teams. Our approach is simple: we invest in what we know. Over the course of our respective careers the Gore Range teamhas built domain expertise and extensive networks across multiple areas of healthcare. Through Gore Range Capital we are channeling our capabilities to focus on our largest organ and the most visible manifestation of who we are - the skin.At Gore Range, we blend the hands-on approach of operationally focused private equity with the early-stage guidance needed in venture capital. We offer not just capital, but insights as well as operational, clinical, and scientific expertise while leveraging our deep industry relationships to position our portfolio companies for success.

## Contacts

5 contacts available for Gore Range Capital. Shizune tracks 5 team members at Gore Range Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/gorerange-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 55% |
| Biotechnology | 5 | 45% |
| mHealth | 2 | 18% |
| Software | 2 | 18% |
| Life Science | 2 | 18% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 27% |
| Seed | 2 | 18% |
| Series B | 1 | 9% |
| Series D | 1 | 9% |
| Series F | 1 | 9% |

8 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Chidi Nwankpa, MD | Principal | 0 | — |
| Ethan Rigel | Founding Partner | 0 | — |
| Frank DeBernardis | Operating Partner | 0 | — |
| Humberto Antunes | Partner | 0 | — |
| Ting Pau Oei | Venture Partner | 1 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Palvella Therapeutics | Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania. |  | Post-IPO Equity | Dec 13, 2024 |  |
| AOA | AOA Dx is a biotechnology company with a team of entrepreneurs that brings innovative, impactful, and cost-effective medical technologies from research and development into the hands of providers and patients. The company is driven by a mission to bring to market the first accurate early-stage non-invasive ovarian cancer diagnostic test that willimprove clinical practice and help reduce patient mortality. | $17M |  | Oct 11, 2023 |  |
| AOA | AOA Dx is a biotechnology company with a team of entrepreneurs that brings innovative, impactful, and cost-effective medical technologies from research and development into the hands of providers and patients. The company is driven by a mission to bring to market the first accurate early-stage non-invasive ovarian cancer diagnostic test that willimprove clinical practice and help reduce patient mortality. | $17M | Series A | Oct 11, 2023 |  |
| Palvella Therapeutics | Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania. | $37.7M | Series D | Jan 05, 2023 |  |
| Validic | Validic is the healthcare industry's premier technology platform for convenient, easy data access to a world of mobile health and in-home devices, fitness equipment, clinical sensors, activity wearables, smart bands, and wellness applications. Founded in 2010, Validic is headquartered in Durham, North Carolina. | $12M | Venture - Series Unknown | Nov 14, 2022 |  |
| Eirion Therapeutics | Eirion Therapeutics is a clinical-stage biopharmaceutical company that is developing next-generation prescription products for aesthetic dermatology. The company currently has a rich pipeline of products focusing on treatments for wrinkles, primary axillary hyperhidrosis, androgenic alopecia, and hair greying. In the future, Eirion plans to alsopursue additional indications that address other major unmet clinical needs for physicians and their patients. | $40M | Series A | Mar 09, 2021 |  |
| Dorsata | Dorsata enables healthcare providers to make better decisions that are informed by data and best practices. The company provides teams of clinicians tools to build, share, and then use defined workflows, called care pathways, for efficient decision-making, documentation, and order entry. Leveraging these clinician-developed care pathways, Dorsatais committed to transforming healthcare from a cost-reduction and quality improvement standpoint.Dorsata was founded in 2011 and is headquartered in Washington, District of Columbia, United States. | $5.2M | Series A | Apr 09, 2020 |  |
| Paradigm Diagnostics | Paradigm brings cutting-edge diagnostics and biomarker driven clinical trials to benefit cancer patients.Through Next-Gen Sequencing, and other biomarker analysis, Paradigm is able to provide information about the genomic and proteomic landscape of a patient’s cancer, as well as potential therapies based on the specific characterization of thepatient’s tumor; thus, personalizing each patient’s course of treatment. | $15M | Series B | May 21, 2019 |  |
| Conversa Health | Conversa enables health systems to virtually engage, monitor and manage patients for chronic care, acute discharge, perioperative, oncology, OBGYN, prevention and wellness, and more. The automated care platform engages patients at high frequency and scale, while triaging to care venues when necessary, optimizing and improving the use of telehealthe-visits, phone calls and in-person consults. Conversa’s suite of COVID-19 Virtual Care Programs is being used by innovative organizations like UCSF Health, Northwell, UNC Health, Prisma Health and University Hospitals to provide symptom checking and triage, provide check-ins with quarantined patients, deliver lab results and screen employees, patients and visitors. | $2M | Seed | May 10, 2016 |  |
| Dorsata | Dorsata enables healthcare providers to make better decisions that are informed by data and best practices. The company provides teams of clinicians tools to build, share, and then use defined workflows, called care pathways, for efficient decision-making, documentation, and order entry. Leveraging these clinician-developed care pathways, Dorsatais committed to transforming healthcare from a cost-reduction and quality improvement standpoint.Dorsata was founded in 2011 and is headquartered in Washington, District of Columbia, United States. | $1.1M | Seed | Jan 21, 2016 |  |

10 of 11 investments shown.

## Co-investors
- [1776 Ventures](https://shizune.co/investors/profile/1776-ventures) — VC Fund, 2 deals together
- [Adaptive Capital Partners](https://shizune.co/investors/profile/adaptive-capital-partners) — VC Fund, 2 deals together
- [BioAdvance](https://shizune.co/investors/profile/bioadvance) — VC Fund, 2 deals together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/biotechnology-value-fund) — VC Fund, 2 deals together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/bvf-partners-3e10) — VC Fund, 2 deals together
- Cancer Fund — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Gore Range Capital invest in?

Gore Range Capital invests primarily in Health Care, Biotechnology and mHealth startups, most often at Series A and Seed stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Gore Range Capital?

Public channels for Gore Range Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Gore Range Capital?

The team at Gore Range Capital includes Chidi Nwankpa, MD (Principal), Ethan Rigel (Founding Partner) and Frank DeBernardis (Operating Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co